BioLargo (BLGO, Financial) has successfully garnered approval for all proposals presented at its 2025 annual stockholder meeting. One notable resolution that received the green light was the authorization for the company’s board to execute a reverse stock split with a potential ratio of up to 10-for-1. However, the board clarified that there are no immediate intentions to initiate this reverse split. The board plans to consider this option only if necessary to align with the minimum price requirement for an uplisting to either Nasdaq or the New York Stock Exchange.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for BioLargo Inc (BLGO, Financial) is $0.35 with a high estimate of $0.35 and a low estimate of $0.35. The average target implies an upside of 69.08% from the current price of $0.21. More detailed estimate data can be found on the BioLargo Inc (BLGO) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, BioLargo Inc's (BLGO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BioLargo Inc (BLGO, Financial) in one year is $0.36, suggesting a upside of 73.91% from the current price of $0.207. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BioLargo Inc (BLGO) Summary page.
BLGO Key Business Developments
Release Date: May 15, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- BioLargo Inc (BLGO, Financial) is heavily investing in innovative and transformative technologies, focusing on sustainable solutions for human health and the environment.
- The company has a strong focus on intellectual property, with unmatched claims and a robust portfolio of trade secrets and patents.
- BioLargo Inc (BLGO) has established strategic partnerships and spinouts to capitalize on research and development and create value for stockholders.
- The company is actively expanding its team, including engineers and PhDs, to support its growth and innovation efforts.
- BioLargo Inc (BLGO) is pursuing a franchise model for its battery technology, which could lead to significant financial opportunities and scalability.
Negative Points
- BioLargo Inc (BLGO) experienced a decline in revenue for Q1 2025, dropping from $4.7 million to $3.3 million, primarily due to reduced sales of the Poof product.
- The company reported a net loss of $1.9 million, compared to $800,000 in the previous year, indicating financial challenges.
- There is uncertainty and lack of control over the success of the Poof product, which impacts BioLargo Inc (BLGO)'s revenue.
- The company is facing delays in the adoption and market penetration of its technologies, particularly in the regulatory and validation processes.
- BioLargo Inc (BLGO) is operating in a highly competitive and demanding market, which requires significant investment and time to achieve market adoption.
